The Role of Epiretinal Membrane on Treatment of Neovascular Age-Related Macular Degeneration with Intravitreal Bevacizumab

Table 2

Mean best corrected visual acuity and central retinal thickness values at baseline and at the 3-, 6-, 12-, and 24-month follow-up for AMD and AMD/ERM groups.

	AMD group	𝑃 value	AMD/ERM group	𝑃 value
Mean baseline BCVA, logMAR ± SD (range)	0.71±0.28; (0.3–1.3)		0.73±0.31; (0.3–1.3)
Mean BCVA at 3 months, logMAR ± SD (range)	0.61±0.22; (0.2–1.0)	0.02	0.64±0.32; (0.3–1.1)	0.03
Mean BCVA at 6 months, logMAR ± SD (range)	0.63±0.21; (0.3–1.0)	0.11	0.66±0.31; (0.3–1.1)	0.13
Mean BCVA at 12 months, logMAR ± SD (range)	0.63±0.22; (0.3–1.0)	0.13	0.67±0.28; (0.3–1.2)	0.21
Mean BCVA at 24 months, logMAR ± SD (range)	0.66±0.24; (0.3–1.0)	0.39	0.70±0.25; (0.3–1.3)	0.52
Mean baseline CRT, 𝜇m ± SD (range)	315±102; (275–462)		371±95; (298–519)
Mean CRT at 3 months, 𝜇m ± SD (range)	224±63; (172–284)	<0.001	301±86; (221–353)	<0.001
Mean CRT at 6 months, 𝜇m ± SD (range)	257±71; (178–299)	<0.001	322±90; (263–367)	<0.001
Mean CRT at 12 months, 𝜇m ± SD (range)	245±73; (160–312)	<0.001	311±67; (232–380)	<0.001
Mean CRT at 24 months, 𝜇m ± SD (range)	225±62; (153–302)	<0.001	314±77; (240–391)	<0.001

AMD, age-related macular degeneration; ERM, epiretinal membrane; BCVA, best corrected visual acuity; CRT, central retinal thickness; SD, standard deviation.
*One-way ANOVA test for all comparisons.